Daojing Wang, Ph.D., Founder and CEO
Dr. Wang founded Newomics Inc. in August 2011 while a Career Scientist and Principal Investigator at Lawrence Berkeley National Laboratory (LBNL), where he had worked since 2002. Dr. Wang launched Newomics in September 2013 to further its technology development and commercialization. Dr. Wang has been continuously serving as a principal investigator for multiple research grants from NIH, DOE, NASA, and CBCRP. He has published extensively in highly respected journals such as Aging Cell, Analytical Chemistry, Cancer Research, Journal of Proteome Research, Molecular and Cellular Proteomics, Proceedings of the National Academy of Sciences, Proteomics, and Trends in Biotechnology etc. Dr. Wang is the co-inventor of multiple issued and pending patents including M3 emitters, MEA chips, and senescence chips, which together lay the foundation for Newomics’ platforms and solutions for precision medicine. Prior to joining LBNL, Dr. Wang had performed research at SurroMed Inc. and the University of California, San Francisco. Dr. Wang obtained his B.S. degree from University of Science and Technology of China (USTC) in 1994, Ph.D. in Chemistry from Princeton University in 1999, and completed his postdoctoral training at the University of California, Berkeley in 2000.
Doug Henry, Vice President of Operations
Doug has over 30 years of experience in various sales and operations management roles in the Biotechnology tools space. Most recently, he was North American Director of Sales at Bio-Rad. Prior to that, Doug was North American Service and Support Manager at Bio-Rad, overseeing 175 employees with a $25M budget. Doug launched his biotech career in San Diego, working 15 years in sales and sales management at Thermo Fisher Scientific, winning several individual and team performance awards. Doug has been involved in many operation projects including service automation platform (ServiceMax), SAP implementation, eCommerce and freight management improvements, and a Net Promoter customer satisfaction system. Doug holds a bachelor’s degree in microbiology and a master’s degree in public administration, both from the University of Washington.
Frank Slovenec, Chief Commercialization Officer
Frank has over 25 years of experience in building and growing high performance customer facing organizations for a range of high-tech solutions and services companies. Frank was the President and COO of GTSI, a publicly traded company, now UNICOM. He tripled the value of the company in his 3-year tenure, earning him Business Man of the Year honors in Federal Integrator space. Frank started his career in sales and has been Vice President of Sales for a number of public and private companies. Included in those companies is Ingram-Micro. Today Ingram-Micro is the largest computer products distributor in the world. He started SalesCEO, a sales training and sales consulting firm in 2000. SalesCEO has worked with technology and medical device companies authoring sales and business development plans and building organizations. Frank earned a Bachelor of Science degree from Cleveland State University, and is an advisor to Sonitus Technologies and Precise Light Surgical.
Pan Mao, Ph.D., Co-Founder and Director of Product Engineering
Dr. Mao co-founded Newomics Inc. with Dr. Wang in August 2011. Dr. Mao is the co-inventor of M3 emitters and MEA chips. Dr. Mao has extensive experience in developing micro/nanofluidic technologies to solve biological problems. He has made significant contributions to the application of micro/nanofluidics for biological sample preparation and development of fully integrated micro/nanofluidic bioanalytical systems to perform high-throughput omics analysis. Dr. Mao has published over 15 papers in well-respected journals such as Analytical Chemistry, Journal of Proteome Research, and Lab-on-a-Chip, and has served as principal investigator and co-investigator at Newomics Inc. for several NIH SBIR projects. Dr. Mao obtained his B.S. degree from USTC in 2002, Ph.D. in Mechanical Engineering from MIT in 2009, and completed his postdoctoral training at LBNL in 2013.